Peptide Therapy Research: Safety & Efficacy Study

A comprehensive new study published in Sports Medicine has examined the growing landscape of peptide therapies used for musculoskeletal injuries and athletic performance enhancement. The research, conducted by Mendias and Awan, reveals a concerning divide between rigorously tested approved peptides and a "gray market" of unapproved compounds that lack proper regulatory oversight.

What This Study Found

The researchers conducted a narrative review examining both approved and unapproved peptide therapies commonly marketed to patients for sports medicine applications. The study analyzed twelve prominent compounds including AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, thymosin beta-4, and TB-500.

Key findings from the research include:

Regulatory Status Disparities: The study found that while some peptides like tesamorelin (Egrifta) have undergone rigorous approval processes with established safety and efficacy profiles, many others operate in an unregulated space. The researchers noted that "numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy" while "a parallel 'gray market' of unapproved compounds has emerged, operating largely outside of regulatory oversight."

Animal vs. Human Data Gap: The study suggests that many unapproved peptides demonstrate favorable outcomes in animal models for tissue repair and metabolic function. However, researchers emphasized that "rigorous human safety data are scarce, and there is potential for serious harm to patients." This represents a critical knowledge gap between preclinical promise and clinical safety.

Market Demand vs. Evidence: The research found that peptide use in sports medicine is "rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement," despite limited human clinical data for many compounds.

Clinical Significance

This study highlights several important clinical considerations for healthcare providers and patients. The researchers found that peptides occupy "a unique pharmacological niche between small-molecule drugs and large proteins," which may contribute to their therapeutic potential but also complicates their regulation and safety assessment.

The study suggests that the appeal of peptide therapies stems from their potential mechanisms of action in tissue repair and metabolic enhancement. However, the researchers emphasize a critical distinction between compounds with established clinical evidence versus those with only preclinical data.

Particularly concerning is the study's finding regarding the placebo effect as a mediator of peptide efficacy. The researchers noted how social media amplifies this effect, potentially leading patients to perceive benefits that may not reflect the actual therapeutic value of unapproved compounds.

The study also examined alternative treatments that may be considered for musculoskeletal healing and athletic performance, providing healthcare providers with a broader context for treatment decisions.

Current Access and Compliance Context

The research reveals a complex regulatory landscape where approved peptides like tesamorelin have clear guidelines for use, while unapproved compounds exist in what the study terms a "gray market." This creates challenges for both patients and healthcare providers trying to navigate treatment options.

The study found that many unapproved peptides are "marketed direct to patients," bypassing traditional healthcare oversight mechanisms. This direct-to-consumer approach raises concerns about proper medical supervision and informed consent regarding potential risks.

The researchers provided a framework to help healthcare providers "navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance." This framework emphasizes the importance of distinguishing between approved and unapproved compounds when counseling patients.

What Patients Should Know

Based on this research, patients considering peptide therapy should understand several key points:

Regulatory Status Matters: The study suggests that there is a significant difference between peptides that have undergone formal approval processes and those that have not. Approved peptides have established safety profiles and dosing guidelines, while unapproved compounds lack this oversight.

Limited Human Safety Data: For many popular peptides, the researchers found that "rigorous human safety data are scarce." Patients should be aware that positive results in animal studies do not guarantee safety or efficacy in humans.

Potential for Harm: The study specifically noted "potential for serious harm to patients" with unapproved compounds, emphasizing that natural or peptide-based does not automatically mean safe.

Evidence-Based Alternatives: The research examined alternative treatments with more established evidence bases that patients might consider for musculoskeletal healing and performance enhancement.

Healthcare Provider Consultation: The study's framework for patient discussions underscores the importance of working with qualified healthcare providers who can properly assess individual risk-benefit ratios.

Conclusion

This important research by Mendias and Awan provides crucial insights into the current state of peptide therapy for musculoskeletal injuries and athletic performance. The study suggests that while peptides may hold therapeutic promise, the distinction between approved and unapproved compounds is critical for patient safety.

The research emphasizes the need for evidence-based decision-making in peptide therapy selection. As the field continues to evolve, patients and healthcare providers must carefully weigh the potential benefits against the known risks, particularly for unapproved compounds with limited human safety data.

If you're considering peptide therapy, consult with a qualified healthcare provider who can help you navigate these complex treatment options safely. Find a qualified peptide therapy provider to discuss evidence-based treatment options.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment.

Citation: Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;41966639. doi:10.1007/s40279-026-02437-0